Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232491 · ClinicalTrials.gov registry record · Phase 4
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 611
- Enrollment target
- 20
- Study locations
NCT01232491 is a Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 611 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01232491, a Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 611 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes currently treated with oral antidiabetic drugs (OADs).
Conditions Studied
Interventions
- DRUG Insulin detemir
- DIETARY_SUPPLEMENT Dietary regimen
Study Locations (20)
California
- Novo Nordisk Investigational Site - Anaheim
- Novo Nordisk Investigational Site - Burlingame
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Fullerton
- Novo Nordisk Investigational Site - Long Beach
- Novo Nordisk Investigational Site - Long Beach
- Novo Nordisk Investigational Site - Long Beach
- Novo Nordisk Investigational Site - Montclair
- Novo Nordisk Investigational Site - National City
- Novo Nordisk Investigational Site - Redlands
- Novo Nordisk Investigational Site - Santa Ana
- Novo Nordisk Investigational Site - Spring Valley
- Novo Nordisk Investigational Site - Walnut Creek
Florida
- Novo Nordisk Investigational Site - Bradenton
- Novo Nordisk Investigational Site - Clearwater
- Novo Nordisk Investigational Site - Jacksonville
Alabama
- Novo Nordisk Investigational Site - Birmingham
- Novo Nordisk Investigational Site - Ozark
Colorado
- Novo Nordisk Investigational Site - Colorado Springs
Connecticut
- Novo Nordisk Investigational Site - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2010-10-29 |
| Est. Completion | 2011-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232491
The ClinicalTrials.gov registry entry for NCT01232491 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Insulin detemir is the first listed.
NCT01232491 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01232491 about?
NCT01232491 is a clinical study titled "Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes". This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes currently treated with oral antidiabetic drugs (OADs).
What is the current status of trial NCT01232491?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 611 participants. The study started on 2010-10-29. Estimated completion is 2011-11-14.
What conditions does trial NCT01232491 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.
What interventions are being tested in trial NCT01232491?
The interventions under investigation include: Insulin detemir (DRUG), Dietary regimen (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01232491?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01232491 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.